Does Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?
Journal of Innate Immunity · 11.12.2024 · 17 (1) · 44-55
DOI: 10.1159/000543083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Innate Immunity, online erschienen am 11.12.2024. Verfasst von Luke Forde und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, Royal College of Surgeons in Ireland, University of Medicine and He…. Hauptthemen laut MEDLINE: Adenosine Triphosphate, Pulmonary Fibrosis, Receptors, Purinergic, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Interstitial lung diseases (ILD) are poorly understood disorders characterised by diffuse damage to the lung parenchyma, with inflammation and fibrosis. Some manifest a progressive fibrotic phenotype with high fatality and limited treatment options, such as idiopathic pulmonary fibrosis. Summary: The degree to which inflammation plays a role in fibrosis progression is unknown. However, wound healing and fibrosis are intricate processes influenced by various inflammatory factors. Extracellular nucleosides and nucleotides, including adenosine triphosphate, activate pro-inflammatory responses to innate immunity and are widely implicated in tissue fibrosis across different organs. The pro-inflammatory effects of extracellular nucleotides occur via P1 and P2 purinergic receptors, expressed across the lung and immune system, and have been implicated in various pulmonary diseases including pulmonary fibrosis. This review amalgamates available data on the complex role of P1 and P2 purinergic receptor signalling in pulmonary fibrosis and discusses perspectives for novel treatments. Key Messages: Purinergic signalling plays a complex and pivotal role in pulmonary fibrosis, warranting further study. The intricate interplay between P1 and P2 receptor pathways necessitates a comprehensive approach to understand their collective impact. While evidence from preclinical models is promising, human studies are essential for further understanding of pulmonary fibrosis. Advances in receptor-specific agonists and antagonists provide novel avenues for research and may ultimately lead to new therapies for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland, lukeforde23@rcsi.ie.
- Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland, lukeforde23@rcsi.ie.
- Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
- Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland.
- School of Medicine, University College Dublin, Dublin, Ireland.
Zitieren
APA
Forde, L., Gogoi, D., Baird, R., McCarthy, C., Keane, M. P., Reeves, E. P., & McGrath, E. E. (2024). Does Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?. Journal of Innate Immunity, 17(1), 44-55. https://doi.org/10.1159/000543083
Vancouver
Forde L, Gogoi D, Baird R, McCarthy C, Keane MP, Reeves EP, et al. Does Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?. Journal of Innate Immunity. 2024;17(1):44-55. doi:10.1159/000543083
BibTeX
@article{Forde2024,
author = {Forde, Luke and Gogoi, Debananda and Baird, Rory and McCarthy, Cormac and Keane, Michael P and Reeves, Emer P and McGrath, Emmet E},
title = {Does Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?},
journal = {Journal of Innate Immunity},
year = {2024},
volume = {17},
number = {1},
pages = {44--55},
doi = {10.1159/000543083}
}
EUVIMED